(0.34%) 5 117.35 points
(0.34%) 38 368 points
(0.39%) 15 990 points
(-0.97%) $83.04
(5.36%) $2.03
(0.35%) $2 355.40
(0.50%) $27.67
(4.12%) $960.05
(-0.26%) $0.932
(-0.47%) $10.97
(-0.57%) $0.796
(1.66%) $93.40
3 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 8.98%
@ $42.61
発行日: 15 2月 2024 @ 04:47
リターン: 5.35%
前回のシグナル: 2月 14 - 05:34
前回のシグナル:
リターン: 1.44 %
Live Chart Being Loaded With Signals
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1...
Stats | |
---|---|
本日の出来高 | 349 418 |
平均出来高 | 607 741 |
時価総額 | 2.60B |
EPS | $0 ( 2024-02-27 ) |
次の収益日 | ( $-0.830 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -14.96 |
ATR14 | $0.0710 (0.16%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-12-19 | Shuman Harry | Sell | 115 | Common Shares |
2023-12-15 | Silverman Peter B. | Buy | 1 286 | Common Shares |
2023-12-15 | Silverman Peter B. | Buy | 21 100 | Common Shares |
2023-12-15 | Silverman Peter B. | Sell | 21 100 | Share Option (right to buy) |
2023-12-15 | Silverman Peter B. | Sell | 22 386 | Common Shares |
INSIDER POWER |
---|
69.28 |
Last 99 transactions |
Buy: 2 523 001 | Sell: 3 636 553 |
ボリューム 相関
Merus NV 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Merus NV 相関 - 通貨/商品
Merus NV 財務諸表
Annual | 2023 |
収益: | $43.95M |
総利益: | $-83.46M (-189.91 %) |
EPS: | $-3.00 |
FY | 2023 |
収益: | $43.95M |
総利益: | $-83.46M (-189.91 %) |
EPS: | $-3.00 |
FY | 2022 |
収益: | $41.59M |
総利益: | $29.60M (71.19 %) |
EPS: | $-2.92 |
FY | 2021 |
収益: | $49.11M |
総利益: | $0.00 (0.00 %) |
EPS: | $-1.730 |
Financial Reports:
No articles found.
Merus NV
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。